SCHEDULE: Vanguard Discloses 5.02% Stake in Tonix Pharmaceuticals

The Vanguard Group has reported a 5.02% beneficial ownership stake in Tonix Pharmaceuticals Holding Corp. as of December 31, 2025.

Summary

• The Vanguard Group, an investment adviser, reported beneficial ownership of 673,605 shares of Tonix Pharmaceuticals Holding Corp. Common Stock.
• This ownership represents 5.02% of the class of securities outstanding.
• Vanguard holds shared voting power over 79,137 shares and shared dispositive power over all 673,605 shares.
• The filing notes an internal realignment within The Vanguard Group, Inc. effective January 12, 2026, where it no longer performs portfolio management or administers proxy voting, with subsidiaries expected to report beneficial ownership separately.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal. While a 13G is a routine disclosure, the presence of a major institutional investor like Vanguard with a 5.02% stake can be interpreted as a positive indicator of institutional confidence in Tonix Pharmaceuticals.

Positives

• The Vanguard Group, a major institutional investor, holds a significant 5.02% stake in Tonix Pharmaceuticals, indicating institutional interest.

Management Comments

• On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. As of that date, The Vanguard Group, Inc. no longer performs portfolio management services or administers proxy voting.
• In accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. anticipates that certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that currently have, or are deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release.
• These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment.
• By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.

Industry Context

StockSavvy.ai notes that the disclosure of a significant stake by a major institutional investor like The Vanguard Group in a pharmaceutical company such as Tonix Pharmaceuticals can be viewed as a vote of confidence in the company's long-term prospects, particularly given the capital-intensive and high-risk nature of drug development. This institutional backing often signals a degree of fundamental analysis and belief in the company's strategic direction or pipeline potential.

Comparison to Industry Standards

• This Schedule 13G filing by The Vanguard Group is a standard regulatory disclosure for institutional investors acquiring more than 5% beneficial ownership in a public company.
• The reporting of shared voting and dispositive power is typical for large asset managers like Vanguard, which manage funds on behalf of numerous clients.
• The internal realignment mentioned by Vanguard is an internal operational change, not directly comparable to issuer-specific industry benchmarks, but reflects standard practices for large, diversified financial institutions to optimize their operational structure and regulatory compliance.

Management Changes

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by Vanguard may instill confidence among existing shareholders and potentially attract new investors, as it signals a major player's belief in the company.
• Management: The presence of a large institutional investor like Vanguard can lead to increased scrutiny and engagement regarding corporate strategy and performance.

Next Steps

• The Vanguard Group anticipates that certain subsidiaries or business divisions will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on SEC Release No. 34-39538.

Key Dates

Recommendation

While the disclosure of a 5.02% stake by The Vanguard Group is a positive signal of institutional interest, this filing is purely an ownership report and does not provide new information on Tonix Pharmaceuticals' operational performance, financial health, or strategic developments. Therefore, a 'hold' recommendation is appropriate, suggesting investors maintain their current position while awaiting further fundamental updates from the company itself.

Keywords

Tonix Pharmaceuticals, Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, TNXP, Pharmaceuticals